These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38709422)

  • 21. Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.
    Gross AM; Frone M; Gripp KW; Gelb BD; Schoyer L; Schill L; Stronach B; Biesecker LG; Esposito D; Hernandez ER; Legius E; Loh ML; Martin S; Morrison DK; Rauen KA; Wolters PL; Zand D; McCormick F; Savage SA; Stewart DR; Widemann BC; Yohe ME
    Am J Med Genet A; 2020 Apr; 182(4):866-876. PubMed ID: 31913576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.
    Bai RY; Esposito D; Tam AJ; McCormick F; Riggins GJ; Wade Clapp D; Staedtke V
    Gene Ther; 2019 Jun; 26(6):277-286. PubMed ID: 31127187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAS and beyond: the many faces of the neurofibromatosis type 1 protein.
    Anastasaki C; Orozco P; Gutmann DH
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35188187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.
    Somatilaka BN; Madana L; Sadek A; Chen Z; Chandrasekaran S; McKay RM; Le LQ
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38502231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
    Weiss B; Bollag G; Shannon K
    Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurofibromatosis type 1: New developments in genetics and treatment.
    Wilson BN; John AM; Handler MZ; Schwartz RA
    J Am Acad Dermatol; 2021 Jun; 84(6):1667-1676. PubMed ID: 32771543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?
    Fareez F; Wang BH; Brain I; Lu JQ
    Pathology; 2023 Apr; 55(3):302-314. PubMed ID: 36774237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
    Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
    Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
    Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
    Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
    Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.
    Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA
    Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy.
    Cui XW; Ren JY; Gu YH; Li QF; Wang ZC
    Curr Gene Ther; 2020; 20(2):100-108. PubMed ID: 32767931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer.
    Rad E; Tee AR
    Semin Cell Dev Biol; 2016 Apr; 52():39-46. PubMed ID: 26860753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Emerging Role of Ras Pathway Signaling in Pediatric Cancer.
    Ney GM; McKay L; Koschmann C; Mody R; Li Q
    Cancer Res; 2020 Dec; 80(23):5155-5163. PubMed ID: 32907837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications.
    Marjanska A; Galazka P; Wysocki M; Styczynski J
    Anticancer Res; 2020 Apr; 40(4):1817-1831. PubMed ID: 32234870
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Giraud JS; Bièche I; Pasmant É; Tlemsani C
    Expert Opin Investig Drugs; 2023; 32(10):941-957. PubMed ID: 37747491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
    Tamura R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
    Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
    J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel mutation in NF1 gene of patient with Neurofibromatosis type 1: A case report and functional study.
    Zhang T; Jia C; Dong Z; Li C; Lu W
    Mol Genet Genomic Med; 2021 May; 9(5):e1643. PubMed ID: 33764694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.